XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Shares of XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.56 and traded as low as $2.07. XTL Biopharmaceuticals shares last traded at $2.23, with a volume of 26,382 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research report on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

The company has a 50-day simple moving average of $2.55 and a 200-day simple moving average of $4.57. The stock has a market cap of $5.10 million, a P/E ratio of -3.63 and a beta of 1.48.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.